Initiating statin therapy shortly after a type 2 diabetes diagnosis may be associated with a reduced risk of developing dementia, according to a large study presented at the European Society of Cardiology Congress. The research, published in The Lancet Regional Health – Europe, found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of dementia over 10 years compared to those who did not take the medication within five years.
Statins are prescription medications designed to lower LDL cholesterol, commonly known as "bad" cholesterol, and are widely prescribed to reduce the risk of heart attack and stroke. People diagnosed with type 2 diabetes already face an elevated risk for both cognitive decline and heart disease, consistent with previous research.
The study analyzed health data from over 132,000 patients in Denmark who were diagnosed with type 2 diabetes between 2006 and 2019 and had no prior history of statin use or dementia. Researchers tracked these individuals for a median of 7.1 years to examine the impact of statin treatment timing on overall dementia rates.
For individuals who delayed starting statins for one to five years after their diagnosis, the study observed a 10% lower relative risk of dementia. These findings suggest a potential benefit to earlier intervention with statin therapy.
Dr. Liron Sinvani, a geriatrician and director for research and innovation at the Northwell Institute for Healthy Aging, described the study as "well-designed" and noted that it adds to emerging evidence suggesting statins may play a role in protecting brain health. She highlighted that the observed 15% reduction, while modest, is significant. Sinvani found the results particularly compelling because the reduced risk was primarily linked to vascular dementia, rather than Alzheimer's disease. She explained this connection by noting that statins' known mechanisms—lowering cholesterol, reducing inflammation, and protecting blood vessels—are also crucial in preventing vascular damage to the brain.
While current guidelines often recommend statins for adults between 40 and 75 with diabetes, prompt initiation after diagnosis is not always standard practice. Sinvani suggested that the study's findings indicate that delaying statin treatment might not be the optimal approach for patients with type 2 diabetes.
The study's authors cautioned that because it was an observational study rather than a randomized controlled trial, a direct causal link between statins and dementia prevention cannot be definitively proven. However, Sinvani stated, "This is not proof that statins prevent dementia, but I think it's an important step in this literature." She encouraged individuals with type 2 diabetes who are not currently on statin therapy to discuss its appropriateness with their healthcare provider.
Experts emphasize that statin therapy should be considered part of a comprehensive health strategy that includes regular exercise, a healthy diet, and social engagement. According to The Lancet Commission, nearly half of all dementia cases may be preventable or delayable by addressing modifiable risk factors.